Omniscan (Gadodiamide)

Gadodiamide, the active ingredient in Omniscan, is a contrast media presented as a 0.5 ml/mL solution for intravenous use. It enhances magnetic resonance imaging (MRI) scans to improve visualization of vascular structures and tissue characteristics in adult patients. GNH USA supplies Omniscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and imaging centres worldwide.

GNH USA supplies Omniscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and imaging centres worldwide.

Omniscan is a gadolinium‑based contrast agent used in magnetic resonance imaging to highlight anatomical details. - Central nervous system imaging: improves lesion detection and delineation in the brain and spinal cord. - Vascular imaging: enhances visualization of arteries, veins and vascular malformations. - Body imaging: increases contrast of abdominal and pelvic organs for better lesion characterization.

Adverse reactions to Omniscan are generally mild but can vary in severity.

Common Side Effects: - Nausea: mild, transient feeling of stomach upset. - Headache: mild to moderate discomfort. - Injection site discomfort: pain or burning at the infusion site. - Warm sensation: brief feeling of warmth or flushing. - Dizziness: light‑headed feeling shortly after administration.

Serious or Rare Side Effects: - Nephrogenic systemic fibrosis (NSF): fibrotic skin changes in patients with severe renal impairment. - Anaphylactoid reaction: severe allergic response requiring immediate medical attention. - Severe hypotension: sudden drop in blood pressure. - Cardiac arrest: rare but life‑threatening event. - Pulmonary edema: fluid accumulation in the lungs. - Acute kidney injury: rapid decline in renal function.

Omniscan should be used with careful assessment of patient risk factors and under professional supervision. - Renal function assessment: evaluate glomerular filtration rate before administration. - History of allergic reactions: review prior contrast media reactions. - Pregnancy: avoid unless clearly needed, as safety data are limited. - Breastfeeding: consider discontinuation during treatment. - Concomitant nephrotoxic drugs: use with caution. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Omniscan may interact with other agents that affect renal function or hypersensitivity risk.

Major Interactions (Avoid): - High‑dose intravenous iodinated contrast: increases risk of renal toxicity. - Nephrotoxic antibiotics (e.g., aminoglycosides): may compound kidney injury.

Moderate Interactions (Monitor Closely): - Loop diuretics: may alter fluid balance and affect renal clearance. - ACE inhibitors or ARBs: monitor renal function closely when combined. - NSAIDs: can reduce renal perfusion, increasing risk of nephrotoxicity. - Calcium channel blockers: may influence vascular response during injection.